Amyris expects to receive cash representing a short-term collaboration investment of $10 million, an equity investment of up to $20 million at $1.40 per share, $100 million in annual revenue starting in 2017 connected to the production and cost improvement of fermentation molecules, and participation in the partner's industrial fermentation facilities in Asia.
This relationship follows a series of significant partnerships Amyris has announced in recent months, including a partnership with a separate company in the nutraceuticals space that was announced on September 30, 2016.
"We're very pleased with the opportunity to partner with one of the leading nutraceutical and food ingredient suppliers in the world. Our current annual revenue run rate of over $100 million combined with the $100 million of annual revenue we expect from this partnership starting in 2017, should help us deliver stronger than expected growth in 2017 and beyond," said John Melo, Amyris President & CEO.
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, in collaboration with the Autodesk BioNano Research Group, today announced the immediate availability of powerful open source tools for genetic design that leverage Autodesk's Genetic Constructor, an extensible, open source, cloud CAD tool, and Amyris's open source Genotype Specification Language ("GSL"), to more rapidly drive biological design and complex DNA construction. Autodesk BioNano Research and Amyris will be showcasing this solution today at SynBioBeta SF 2016 in San Francisco.
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has expanded its strategic partnership with a global nutraceuticals market leader. The new agreement represents a significant expansion in expected revenue compared to the prior agreement announced on April 27, 2016, and includes the addition of a new nutraceutical target, a credit line of up to $25 million with a 5-year maturity, and an option for a $5-million strategic investment from one of the world's leading nutraceuticals manufacturers.
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has completed a subsequent collaboration agreement with Ginkgo Bioworks, which is expected to be approved by the boards of both companies. The agreement finalizes details of how the two companies will jointly develop cultured products more efficiently and cost effectively, accelerating time to market. This breakthrough biotech collaboration was initially announced on June 29, 2016 and, upon board approval, both companies plan to move quickly to establish a leading position within the market for sustainable, bio-based products.
Per the agreement, Ginkgo and Amyris will share in the value of new cultured ingredients brought to market across several industries including food and nutrition, flavor and fragrance, and cosmetics and personal care. These ingredients, produced via fermentation with engineered microorganisms, leverage the end-to-end biotechnology stack that Ginkgo and Amyris have developed, from high throughput automated strain development, analytics, and optimization, to process development, full-scale manufacturing, and product recovery operations.
Biossance™, the pioneer of sustainable beauty through biotechnology from Amyris, Inc. (Nasdaq:AMRS), has introduced The Illuminator, a dual peptide, weightless eye gel with exceptional clinical results.
"The Illuminator is a fantastic, natural solution designed specifically for the delicate eye area to keep you looking fresh and radiant. It's essential to have such an innovative product that's free from harmful ingredients," said Katey Denno, an A-list celebrity makeup artist known for her extensive knowledge of green beauty.
This new, nontoxic product uses weightless, hydrating, 100% plant-derived squalane with dual peptides to reduce the appearance of dark circles and puffiness along with cell extract from Swiss apples to rejuvenate the delicate skin around the eye area. The product's ingredients assist with lymphatic drainage supporting a reduction in bagginess around the eyes, which is often associated with lymph fluid pooling under the skin. The Illuminator is also clinically proven to increase cutaneous microcirculation, breaking up the concentration of red blood cells under the eye and reducing the appearance of dark circles.
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has won a three-year multi-million dollar contract from the U.S. Department of Energy (‘DOE') to further the manufacturing of cellulose-derived farnesene for biofuels. Amyris, in cooperation with Renmatix and Total New Energies USA (‘Total'), will work to develop a manufacturing-ready process utilizing wood as the cellulosic feedstock to produce farnesene, a hydrocarbon building block used to manufacture a variety of products ranging from cosmetics to detergents, as well as base oils, lubricants, diesel and jet fuel.
"We're pleased to partner with Renmatix and Total in furthering the advancement of cellulose-derived farnesene," said John Melo, President & CEO of Amyris. "Success in this project could enable farnesene cost below $1 a liter, which will deliver breakthrough results in a variety of products, including biofuels, while at the same time leveraging the existing large forestry infrastructure to utilize renewable wood sources and wood waste as a sugar source to produce it."
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is pleased to announce it has entered into a funded partnership with Biogen, Inc. (Nasdaq:BIIB). The collaboration will explore the use of Amyris's advanced microbe engineering technology to evaluate and develop multiple host microorganisms as alternatives to mammalian cell lines for the production of therapeutic recombinant proteins.
"We are pleased to have signed our second major partnership in the biopharma market and we believe with Biogen, the biopharma market is now well positioned to become our largest opportunity for collaborations," said Cynthia Bryant, Amyris Senior Vice President Corporate Development & Collaborations.
For many recombinant protein therapeutics, mammalian cell lines are engineered to produce the needed protein using a fermentation process. While tremendous progress has been made in increasing productivity, limitations remain.
"Over the course of the partnership, Amyris will utilize its leading strain engineering and screening technology to evaluate the tractability of each selected species as a new potential cell line for recombinant protein production," explained Joel Cherry, Amyris's President, Research and Development. "Selected candidates from the initial work will go into a second phase of development to create commercially robust cell lines for use in drug manufacturing."
News 
Market Data 
Discover 
